Mga Batayang Estadistika
| CIK | 352747 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Unigene Laboratories, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 2, 2013 |
ugne201307028k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorpora |
|
| June 17, 2013 |
ugne20130617b8kex10-1.htm Exhibit 10.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SE |
|
| June 17, 2013 |
Exhibit 10.3 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) AN O |
|
| June 17, 2013 |
ugne20130617b8kex10-4.htm Exhibit 10.4 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SE |
|
| June 17, 2013 |
ugne20130617b8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorpo |
|
| June 17, 2013 |
EX-10 3 ugne20130617b8kex10-2.htm EXHIBIT 10.2 Exhibit 10.2 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AN |
|
| June 13, 2013 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 10)* UNIGENE LABORATORIES, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 904753100 (CUSIP Number) Scott R. Zemnick, Esq. Victory Park Capital Advisors, LLC 227 W. Monroe Street, Suite 3900 Chicago, Il |
|
| June 7, 2013 |
8-K 1 ugne201306078k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdicti |
|
| June 7, 2013 |
ugne201306078kex10-1.htm Exhibit 10.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SEC |
|
| May 29, 2013 |
8-K 1 ugne201305298k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdicti |
|
| May 24, 2013 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* UNIGENE LABORATORIES, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 904753100 (CUSIP Number) Scott R. Zemnick, Esq. Victory Park Capital Advisors, LLC 227 W. Monroe Street, Suite 3900 Chicago, Ill |
|
| May 20, 2013 |
ugne201305208k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorpora |
|
| May 20, 2013 |
ugne201305208kex10-1.htm Exhibit 10.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SEC |
|
| May 17, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K/A ugne201305178ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorp |
|
| May 17, 2013 |
ugne201305178kaex99-1.htm Exhibit 99.1 Unigene Announces First Quarter 2013 Financial Results and Provides Corporate Update -Management to host conference call on May 14, 2013 at 11 a.m. ET- May 14, 2013 – BOONTON, N.J. - Unigene Laboratories, Inc. (PINK: UGNE) today announced financial results for the first quarter ended March 31, 2013 and provided a corporate update on the Company’s financial st |
|
| May 14, 2013 |
10-Q 1 unigene10q-033113.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm |
|
| May 14, 2013 |
ugne201305148kex99-1.htm Exhibit 99.1 Unigene Announces First Quarter 2013 Financial Results and Provides Corporate Update -Management to host conference call on May 14, 2013 at 11 a.m. ET- May 14, 2013 – BOONTON, N.J. - Unigene Laboratories, Inc. (PINK: UGNE) today announced financial results for the first quarter ended March 31, 2013 and provided a corporate update on the Company’s financial sta |
|
| May 14, 2013 |
Financial Statements and Exhibits, Other Events 8-K 1 ugne201305148k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdicti |
|
| May 13, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 ugne201305108k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdictio |
|
| May 13, 2013 |
ugne201305108kex99-1.htm Exhibit 99.1 Unigene and Nordic Bioscience Enter Equity Transfer and Exclusive License Agreement for Proprietary Metabolic Peptide Analogs Agreement Provides Unigene with Immediate Capital Infusion, as Well as Potential Royalty and Milestone Payments MAY 9, 2013 – Boonton, NJ – Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design and development of peptide-based |
|
| May 3, 2013 |
Amendment No. 8 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* UNIGENE LABORATORIES, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 904753100 (CUSIP Number) Scott R. Zemnick, Esq. Victory Park Capital Advisors, LLC 227 W. Monroe Street, |
|
| May 1, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizat |
|
| May 1, 2013 |
EX-10.3 4 ex10-3.htm EX. 10.3 Exhibit 10.3 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STAT |
|
| May 1, 2013 |
EX-10.4 5 ex10-4.htm EX. 10.4 Exhibit 10.4 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STAT |
|
| May 1, 2013 |
EX-10.2 3 ex10-2.htm EX. 10.2 Exhibit 10.2 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STAT |
|
| May 1, 2013 |
EX-10.1 2 ex10-1.htm EX. 10.1 Exhibit 10.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STAT |
|
| April 30, 2013 |
Exhibit 31.1(a) CERTIFICATION I, Ashleigh Palmer, certify that: 1. I have reviewed this Annual Report on Form 10-K/A Amendment No. 1 of Unigene Laboratories, Inc.; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were ma |
|
| April 30, 2013 |
Exhibit 31.2(a) CERTIFICATION I, Brian Zietsman, certify that: 1. I have reviewed this Annual Report on Form 10-K/A Amendment No. 1 of Unigene Laboratories, Inc.; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were mad |
|
| April 30, 2013 |
10-K/A 1 ugne10ka-123112.htm FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from t |
|
| April 23, 2013 |
Financial Statements and Exhibits, Other Events 8-K 1 ugne201304228k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdic |
|
| April 23, 2013 |
Victory Park Capital Completes Public Auction of Unigene’s Peptelligence™ Drug Delivery Platform ugne201304228kex99-1.htm Exhibit 99.1 Victory Park Capital Completes Public Auction of Unigene’s Peptelligence™ Drug Delivery Platform April 17, 2013 – Boonton, NJ – Unigene Laboratories, Inc. (PINK: UGNE), today announced that on April 16, 2013, Victory Park Capital Advisors, LLC (VPC) held a public auction conducted in accordance with Article 9 of the Uniform Commercial Code (UCC) for the sale o |
|
| April 16, 2013 |
ugne201304158kex16-1.htm Exhibit 16.1 |
|
| April 16, 2013 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 ugne201304158k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdic |
|
| April 12, 2013 |
8-K 1 ugne201304128k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdict |
|
| April 12, 2013 |
ugne201304128kex99-1.htm Exhibit 99.1 - Unigene Secures Financing to Extend Operating Runway in Conjunction with Strategic Reorganization - - Victory Park Capital Commences Process for Potential Sale of PeptelligenceTM Drug Delivery Platform - April 8, 2013 – Boonton, NJ – Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therap |
|
| April 12, 2013 |
ugne201304128kex10-2.htm Exhibit 10.2 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SEC |
|
| April 12, 2013 |
SECOND AMENDMENT AMENDED AND RESTATED FINANCING AGREEMENT ugne201304128kex10-1.htm Exhibit 10.1 SECOND AMENDMENT TO AMENDED AND RESTATED FINANCING AGREEMENT This SECOND AMENDMENT TO AMENDED AND RESTATED FINANCING AGREEMENT (this “Amendment”) is made and entered into as of April 8, 2013 by and among Unigene Laboratories, Inc., a Delaware corporation (“Principal Borrower”), the financial institutions party hereto as “Lenders” (collectively, “Lenders”), and |
|
| April 12, 2013 |
SC 13D/A 1 d520642dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* UNIGENE LABORATORIES, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 904753100 (CUSIP Number) Scott R. Zemnick, Esq. Victory Park Capital Advisors, LLC 227 W. Monroe S |
|
| April 5, 2013 |
Material Impairments, Costs Associated with Exit or Disposal Activities - FORM 8-K ugne201304048k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorpor |
|
| March 15, 2013 |
AMENDMENT NO. 1 TO MASTER AGREEMENT FOR JOINT DEVELOPMENT VEHICLE Exhibit 10.73 AMENDMENT NO. 1 TO MASTER AGREEMENT FOR JOINT DEVELOPMENT VEHICLE THIS AMENDMENT NO. 1 (this “Amendment”) is entered into as of the 15th day of August, 2012 (the “Amendment No. 1 Effective Date”) by and between Unigene Laboratories, Inc., a Delaware corporation (“Unigene”) and Nordic Bioscience Clinical Development A/S, a Danish limited liability company (“Nordic”), and amends that c |
|
| March 15, 2013 |
10-K 1 uni10k-123112.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number |
|
| March 15, 2013 |
Exhibit 10.106 SETTLEMENT AGREEMENT THIS SETTLEMENT AGREEMENT (the “Settlement Agreement”) is made as of the 21st day of December, 2012 between Ostrolenk Faber LLP (“Ostrolenk”), on the one hand, and Unigene Laboratories, Inc. and Unigene Patent Properties Nos. 1 through 120 (collectively, (“Unigene”), on the other hand. Intending to be legally bound, the parties hereto hereby stipulate and agree |
|
| March 12, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 ugne201303118k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdic |
|
| March 12, 2013 |
bvii201303118kex99-1.htm Exhibit 99.1 Unigene Announces Fourth Quarter and Full-Year 2012 Results -Management to host conference call on March 12, 2013 at 11 a.m. ET- March 11, 2013 – BOONTON, N.J. - Unigene Laboratories, Inc. (PINK: UGNE) today announced financial results for the fourth quarter and full-year ended December 31, 2012 and provided a corporate update on the Company’s financial status |
|
| March 6, 2013 |
Unigene Comments on FDA Advisory Committee Review of Salmon Calcitonin Exhibit 99.1 Unigene Comments on FDA Advisory Committee Review of Salmon Calcitonin March 6, 2013 – Boonton, NJ – Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today commented on the outcome of the Food & Drug Administration (FDA) Advisory Committee Meeting held on March 5th, 2013 to discuss whether the benefit |
|
| March 6, 2013 |
Financial Statements and Exhibits, Other Events 8-K 1 ugne201303068k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2013 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdict |
|
| January 31, 2013 |
Exhibit 10.19 Adam Saravay Partner T. 973.639.2023 F. 973.297.3749 [email protected] McCarter & English, LLP Four Gateway Center 100 Mulberry Street Newark, NJ 07102-4056 T. 973.622.4444 F. 973.624.7070 www.mccarter.com BOSTON HARTFORD NEW YORK NEWARK PHILADELPHIA STAMFORD December 18, 2012 VIA E-MAIL Matthew E. Tashman, Esq. Reed Smith LLP 2500 One Liberty Place Philadelphia, PA 19103 Re: Uni |
|
| January 31, 2013 |
Annual Report - AMENDMENT NO. 2 TO FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 2) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 0-16005 UNIGEN |
|
| January 31, 2013 |
10-Q 1 unigene10q-093012.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| January 31, 2013 |
Quarterly Report - FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0 |
|
| January 31, 2013 |
Quarterly Report - FORM 10-Q/A 10-Q/A 1 unigene10qa-033112.htm FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the trans |
|
| December 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organi |
|
| December 21, 2012 |
8-K 1 unigene8k-122112.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jur |
|
| December 19, 2012 |
8-K 1 ugne8k-121912.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisd |
|
| December 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of (Commission File Number |
|
| December 12, 2012 |
Financial Statements and Exhibits, Other Events 8-K 1 ugne8k-121212.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisd |
|
| December 12, 2012 |
Exhibit 99.1 Unigene’s Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone December 12, 2012 – Boonton, NJ – Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral p |
|
| December 12, 2012 |
8-K 1 ugne8k-121212.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2012 (December 7, 2012) Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (St |
|
| December 11, 2012 |
Financial Statements and Exhibits, Other Events 8-K 1 unigene8k-121112.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jur |
|
| December 11, 2012 |
Unigene Engages Financial Advisor to Explore Strategic Options and Advance Corporate Objectives Exhibit 99.1 Unigene Engages Financial Advisor to Explore Strategic Options and Advance Corporate Objectives DECEMBER 11, 2012 – BOONTON, N.J. - Unigene Laboratories, Inc. (OTCBB: UGNE) today announced that it has retained Canaccord Genuity to assist the Company with its exploration and evaluation of a broad range of strategic options, including, but not limited to, the strategic partnering of its |
|
| December 10, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organi |
|
| December 10, 2012 |
EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 December 10, 2012 This letter will confirm my request to cancel the entire award of the 660,000 stock options granted to me under the Employee and Director Retention Grant on September 27, 2012. There will be no cash or other consideration received as a result of this cancellation. Sincerely, /s/ Ashleigh Palmer Ashleigh Palmer Chief Executive Officer |
|
| November 27, 2012 |
EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 UNIGENE AND TARIX PHARMACEUTICALS ENTER DEFINITIVE LICENCING AGREEMENT FOR “PEPTELLIGENCE-ENGINEERED” TXA127 - Licensing Agreement Follows Successful Completion of Feasibility Study of Orally Administered Peptide - November 27, 2012 – Boonton, NJ and Cambridge, MA – Unigene Laboratories, Inc. (OTCBB: UGNE) and Tarix Pharmaceuticals today announced tha |
|
| November 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2012 (November 21, 2012) Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of inc |
|
| November 27, 2012 |
Financial Statements and Exhibits, Other Events 8-K 1 unigene8k-112712.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jur |
|
| November 23, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-16005 CUSIP NUMBER: 904753100 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K þ Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition R |
|
| November 21, 2012 |
EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Unigene Announces Third Quarter 2012 Corporate Update -Third Quarter Highlighted by Forbearance Agreement and First Amendment to Amended and Restated Financing Agreement with Victory Park Capital- -Management to host webcast and conference call today, November 20, 2012 at 11 a.m. ET- NOVEMBER 20, 2012 – BOONTON, N.J. - Unigene Laboratories, Inc. (OTCB |
|
| November 21, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organi |
|
| November 19, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| November 9, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-16005 CUSIP NUMBER: 904753100 (Check One): o Form 10-K o Form 20-F x Form 10-Q o Form 10-D o Form N-SAR For Period Ended: September 30, 2012 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form |
|
| November 9, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organiz |
|
| October 19, 2012 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.91 3 ex10-91.htm EXHIBIT 10.91 EXHIBIT 10.91 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), dated as of September 5, 2012 (the “Amendment Date”), is entered into by and between Unigene Laboratories, Inc., a Delaware corporation (the “Company”), and Gregory T. Mayes (the “Executive”). WITNESSETH: WHEREAS, the Executive is presently emp |
|
| October 19, 2012 |
CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE EX-10.110 4 ex10-110.htm EXHIBIT 10.110 Exhibit 10.110 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE THIS CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE (the “Separation Agreement”) is made and entered into by and between Jenene Thomas (“Employee”) and Unigene Laboratories, Inc. (“Unigene” or the “Company”). RECITALS WHEREAS, Employee has been notified that the Company has decided t |
|
| October 19, 2012 |
Registration Statement - FORM S-1 S-1 1 unigenes1-101912.htm FORM S-1 As filed with the Securities and Exchange Commission on October 19, 2012. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 UNIGENE LABORATORIES, INC. (Exact name of Registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 2833 (Primary S |
|
| October 16, 2012 |
EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Unigene’s Licensee, Tarsa Therapeutics, Reports Positive Clinical Data in Phase 2 Study of Oral Calcitonin for Prevention of Postmenopausal Osteoporosis Results Presented at ASBMR 2012 Show Oral Calcitonin Improves Bone Mineral Density at Lumbar Spine Tarsa to Provide Expert Assistance to Italian Marketer of Nasal Calcitonin Spray, Whose Request for R |
|
| October 16, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation) (Commissi |
|
| October 5, 2012 |
Schedule 13D Amendment No.6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* UNIGENE LABORATORIES, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 904753100 (CUSIP Number) Scott R. Zemnick, Esq. Victory Park Capital Advisors, LLC 227 W. Monroe Street, Suit |
|
| October 3, 2012 |
Exhibit 10.1 SCHEDULE 1 Each of the following executive officers are entitled to the following stock option and bonus compensation pursuant to 2012 Key Employee Performance and Incentive Agreements: Named Executive Officer Stock Options Cash Bonus Ashleigh Palmer, Chief Executive Officer 1,000,000 $ 100,000 Gregory Mayes, President and General Counsel 722,125 $ 72,212 Nozer Mehta, Chief Scientific |
|
| October 3, 2012 |
EX-10.3 4 ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”), dated as of September 27, 2012, is entered into by and between Unigene Laboratories, Inc., a Delaware corporation (the “Company”), and Brian Zietsman (the “Executive”). WITNESSETH: WHEREAS, the Company desires to employ the Executive and to enter into this Agreement embodying the terms of s |
|
| October 3, 2012 |
Exhibit 10.5 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”), dated as of September 27, 2012, is entered into by and between Unigene Laboratories, Inc., a Delaware corporation (the “Company”), and Nozer Mehta (the “Executive”). WITNESSETH: WHEREAS, the Company desires to employ the Executive and to enter into this Agreement embodying the terms of such employment; and WHEREAS, the Exec |
|
| October 3, 2012 |
EX-10.2 3 ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 Schedule 1 Each of the following executive officers and directors are entitled to the following stock options pursuant to Employee and Director Retention Grants: Officer / Director Stock Options Ashleigh Palmer, Chief Executive Officer 660,000 Gregory Mayes, President and General Counsel 287,582 Nozer Mehta, Chief Scientific Officer 190,601 Brian Ziet |
|
| October 3, 2012 |
8-K 1 uni8k-092712.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisd |
|
| October 3, 2012 |
UNIGENE LABORATORIES, INC. FORM OF STOCK OPTION AGREEMENT EX-10.4 5 ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 UNIGENE LABORATORIES, INC. FORM OF STOCK OPTION AGREEMENT AGREEMENT dated as of September 27, 2012 between UNIGENE LABORATORIES, INC., a Delaware corporation, with principal offices at 81 Fulton Street, Boonton, NJ 07005 (the “Company”), and Brian Zietsman, (the “Optionee”). W I T N E S S E T H : WHEREAS, the Company has granted to the Optionee a non- |
|
| September 26, 2012 |
SENIOR SECURED CONVERTIBLE NOTE Exhibit 10.6 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) AN O |
|
| September 26, 2012 |
SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT Exhibit 10.7 EXECUTION VERSION SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (as same may be further amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), dated as of March 17, 2010 and amended and restated as of September 21, 2012, is entered into by and among Unigene Laboratories, Inc |
|
| September 26, 2012 |
Exhibit 10.8 EXECUTION VERSION INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is entered into as of September 21, 2012, by and between Unigene Laboratories, Inc., a Delaware corporation (the “Company”), and Richard N. Levy (“Indemnitee”). RECITALS A. Indemnitee provides a valuable service to the Company by serving as a member of the Board of Directors of the Company (t |
|
| September 26, 2012 |
SECOND AMENDMENT TO RIGHTS AGREEMENT Exhibit 4.1 SECOND AMENDMENT TO RIGHTS AGREEMENT This SECOND AMENDMENT TO RIGHTS AGREEMENT, dated as of September 21, 2012 (this “Second Amendment”), is entered into by and between UNIGENE LABORATORIES, INC., a Delaware corporation (the “Company”), and REGISTRAR AND TRANSFER COMPANY, a New Jersey corporation (the “Rights Agent”). Capitalized terms used but otherwise not defined herein shall have t |
|
| September 26, 2012 |
FORBEARANCE AGREEMENT AND FIRST AMENDMENT TO AMENDED AND RESTATED FINANCING AGREEMENT Exhibit 10.1 EXECUTION VERSION FORBEARANCE AGREEMENT AND FIRST AMENDMENT TO AMENDED AND RESTATED FINANCING AGREEMENT This FORBEARANCE AGREEMENT AND FIRST AMENDMENT TO AMENDED AND RESTATED FINANCING AGREEMENT (this “Amendment”) is made and entered into as of September 21, 2012 by and among Unigene Laboratories, Inc., a Delaware corporation (“Principal Borrower”), the financial institutions party he |
|
| September 26, 2012 |
SENIOR SECURED CONVERTIBLE NOTE Exhibit 10.4 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) AN O |
|
| September 26, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A Amendment No. 2 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 22-2328609 (State of incorporation or organization) (IRS Employer Identification No.) 81 |
|
| September 26, 2012 |
SENIOR SECURED CONVERTIBLE NOTE EX-10.2 4 ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE |
|
| September 26, 2012 |
Exhibit 99.1 Unigene to Target Partnering and Therapeutic Development Opportunities Following Victory Park Capital Debt Financing and Forbearance - Victory Park Capital provides relief from designated default provisions through September 21, 2013 - - $4 million debt financing extends cash runway and enables management to continue momentum of strategic turn-around - - Management to host webcast and |
|
| September 26, 2012 |
EX-10.9 11 ex10-9.htm EXHIBIT 10.9 Exhibit 10.9 PATENT SECURITY AGREEMENT This PATENT SECURITY AGREEMENT (this “Agreement”), dated as of September 21, 2012, by Unigene Laboratories, Inc., a Delaware corporation (the “Grantor”), in favor of Victory Park Management, LLC, as collateral agent (the “Collateral Agent”) for the secured parties referred to below. WHEREAS: A. Reference is made to that cert |
|
| September 26, 2012 |
SENIOR SECURED CONVERTIBLE NOTE Exhibit 10.5 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) AN O |
|
| September 26, 2012 |
Exhibit 10.10 TRADEMARK SECURITY AGREEMENT This TRADEMARK SECURITY AGREEMENT (this “Agreement”), dated as of September 21, 2012, by Unigene Laboratories, Inc., a Delaware corporation (the “Grantor”), in favor of Victory Park Management, LLC, as collateral agent (the “Collateral Agent”) for the secured parties referred to below. WHEREAS: A. Reference is made to that certain Pledge and Security Agre |
|
| September 26, 2012 |
SENIOR SECURED CONVERTIBLE NOTE Exhibit 10.3 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THIS NOTE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR (B) AN O |
|
| September 26, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of (Commission File Numbe |
|
| September 26, 2012 |
Exhibit 10.11 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is entered into as of September 21, 2012, by and between Unigene Laboratories, Inc., a Delaware corporation (the “Company”), and [], a Unigene Laboratories, Inc. Board Director (“Indemnitee”). RECITALS A. Indemnitee provides a valuable service to the Company by serving as a member of the Board of Directors of |
|
| September 19, 2012 |
Exhibit 99.1 UNIGENE AND TARIX PHARMACEUTICALS REPORT HIGHLY INCREASED ORAL BIOAVAILABILITY OF “PEPTELLIGENCE-ENGINEERED” TXA127 - Companies Agree to Definitive Licensing Agreement Following Successful Completion of Feasibility Study of Orally Administered Peptide - September 19, 2012 – Boonton, NJ and Cambridge, MA – Unigene Laboratories, Inc. (OTCBB: UGNE) and Tarix Pharmaceuticals today announc |
|
| September 19, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organ |
|
| September 7, 2012 |
AMENDMENT NO. 1 TO THE UNIGENE LABORATORIES, INC. (a Delaware corporation) Exhibit 3.1 AMENDMENT NO. 1 TO THE BY-LAWS OF UNIGENE LABORATORIES, INC. (a Delaware corporation) WHEREAS, the Board of Directors (the “Board”) of Unigene Laboratories, Inc. (the “Corporation”) desires to amend the By-Laws (the “By-Laws”) of the Corporation, in accordance with Article VII of the By-Laws, effective as of September 5, 2012. NOW, THEREFORE: 1. Article IV, Section 4 of the By-Laws be |
|
| September 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organi |
|
| August 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organiza |
|
| August 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organiza |
|
| August 15, 2012 |
rrd317317358576.html Exhibit 99.1 Explanation of Responses Reporting Person: Victory Park Capital Advisors, LLC Address: 227 West Monroe Street, Suite 3900 Chicago, Illinois 60606 Issuer and Ticker Symbol: Unigene Laboratories, Inc. [UGNE] Relationship of Reporting Director and 10% Owner Person to Issuer: Date of Event 7/16/12 Requiring Statement: Explanation of Responses: Effective as of July 16, |
|
| August 15, 2012 |
EX-99.1 2 rrd317325358596.htm EXPLANATION OF RESPONSES rrd317325358596.html Exhibit 99.1 - Explanation of Responses - Reporting Person: Victory Park GP, LLC Address: c/o Victory Park Capital Advisors, LLC 227 West Monroe Street, Suite 3900 Chicago, Illinois 60606 Issuer and Ticker Unigene Laboratories, Inc. [UGNE] Symbol: Relationship of Director and 10% Owner Reporting Person to Issuer: Date of E |
|
| August 15, 2012 |
Exhibit 99.1 UNIGENE AND NORDIC BIOSCIENCE ANNOUNCE PRELIMINARY SELECTION OF LEAD COMPOUND FOR TREATING TYPE 2 DIABETES -Unigene and Nordic Bioscience to Advance Proprietary Peptide Through Phase 2 Proof-of-Concept Under Incorporated Swiss Entity Joint Development Vehicle- -Composition of Matter Patent Issued Covering Lead Compound and its Use for the Treatment of Diabetes- August 15, 2012 – Boont |
|
| August 9, 2012 |
EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Unigene Announces Second Quarter 2012 Financial Results -Company provides corporate review and status of key strategic initiatives- -Management to host webcast and conference call today, August 9, 2012 at 11 a.m. ET- AUGUST 9, 2012 – BOONTON, N.J. - Unigene Laboratories, Inc. (OTCBB: UGNE) today announced financial results for the second quarter ended |
|
| August 9, 2012 |
10-Q 1 unigene10q-063012.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi |
|
| August 9, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 unigene8k-080912.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisd |
|
| August 9, 2012 |
[Signature Page Follows] READ CAREFULLY BEFORE SIGNING EX-10.2 3 ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 AGREEMENT This AGREEMENT (this “Agreement”) is entered into and is effective this 29th day of May, 2012, respecting the rights and obligations of the following parties (each, a “Party”, and collectively, the “Parties”): 1. Estate of Jean Levy, Jay Levy executor (the “Levy Estate”); 2. The Jaynjean Levy Family Limited Partnership (the “Partnership”); 3 |
|
| August 9, 2012 |
CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE THIS CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE (the “Separation Agreement”) is made and entered into by and between David Moskowitz (“Employee”) and Unigene Laboratories, Inc. (“Unigene” or the “Company”). RECITALS WHEREAS, Employee has notified the Company that he has decided to termin |
|
| August 9, 2012 |
Victory Park Management, LLC 227 W. Monroe Street Suite 3900 Chicago, Illinois 60606 May 29, 2012 EX-10.3 4 ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 Victory Park Management, LLC 227 W. Monroe Street Suite 3900 Chicago, Illinois 60606 May 29, 2012 Unigene Laboratories, Inc. 81 Fulton Street Boonton, New Jersey 07005 Ladies and Gentlemen: We refer to (i) that certain Amended and Restated Financing Agreement, dated as of March 16, 2010, by and among Unigene Laboratories, Inc. (the “Borrower”), the Le |
|
| July 26, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizati |
|
| July 26, 2012 |
EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines -In response to recommendation regarding use of calcitonin-containing medicines, Company requesting access to safety data from relevant European products reviewed by CHMP- July 26, 2012 – BOONTON, N.J. - Unigene Laboratories, Inc. (OTCBB: UGNE) today announc |
|
| July 23, 2012 |
Regulation FD Disclosure - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizati |
|
| July 19, 2012 |
Joint Filing Agreement Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock of Unigene Laboratories, Inc. |
|
| July 19, 2012 |
Schedule 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* UNIGENE LABORATORIES, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 904753100 (CUSIP Number) Scott R. Zemnick, Esq. Victory Park Capital Advisors, LLC 227 W. Monroe Street, Suite 3900 Chicag |
|
| July 19, 2012 |
Redemption Agreement Exhibit 3 REDEMPTION AGREEMENT This Redemption Agreement (this “Agreement”), dated July 16, 2012, is by and between Victory Park Credit Opportunities Intermediate Fund, L. |
|
| July 19, 2012 |
EX-2 3 d384835dex2.htm REDEMPTION AGREEMENT Exhibit 2 REDEMPTION AGREEMENT This Redemption Agreement (this “Agreement”), dated July 16, 2012, is by and between Victory Park Credit Opportunities, L.P., a Delaware limited partnership (“VPCO”), and Victory Park Credit Opportunities Master Fund, Ltd., a Cayman Islands exempted company (the “Master Fund”). WHEREAS, the Master Fund is a private investme |
|
| June 12, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizatio |
|
| June 12, 2012 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”), dated as of June 8, 2012 (the “Effective Date”), is entered into by and between Unigene Laboratories, Inc., a Delaware corporation (the “Company”), and Ashleigh Palmer (the “Executive”). WITNESSETH: WHEREAS, the Company employed Executive pursuant to an agreement dated June 6, 2010 (the “2010 Agreement”) pursuant to which M |
|
| June 8, 2012 |
Regulation FD Disclosure - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizatio |
|
| June 8, 2012 |
Schedule 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* UNIGENE LABORATORIES, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 904753100 (CUSIP Number) Scott R. Zemnick, Esq. Victory Park Capital Advisors, LLC 227 W. Monroe Street, Suite 3900 Chicag |
|
| June 8, 2012 |
Victory Park Management, LLC 227 W. Monroe Street Suite 3900 Chicago, Illinois 60606 May 29, 2012 EX-99.I 2 d364244dex99i.htm LETTER AGREEMENT Exhibit I Victory Park Management, LLC 227 W. Monroe Street Suite 3900 Chicago, Illinois 60606 May 29, 2012 Unigene Laboratories, Inc. 81 Fulton Street Boonton, New Jersey 07005 Ladies and Gentlemen: We refer to (i) that certain Amended and Restated Financing Agreement, dated as of March 16, 2010, by and among Unigene Laboratories, Inc. (the “Borrower”) |
|
| June 6, 2012 |
CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE THIS CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE (the “Separation Agreement”) is made and entered into by and between William Steinhauer (“Employee”) and Unigene Laboratories, Inc. (“Unigene” or the “Company”). RECITALS WHEREAS, Employee has been notified that the Company has decided to t |
|
| June 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizatio |
|
| June 5, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizatio |
|
| June 5, 2012 |
Exhibit 99.1 |
|
| June 4, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizatio |
|
| June 4, 2012 |
Exhibit 99.1 Unigene Enters Agreement to Eliminate 1/3 of its Outstanding $67MM Debt -Management makes significant progress towards addressing debt and restructuring balance sheet- - $22.4MM of Founders’ debt expected to be settled for $8MM plus equity- -Victory Park Capital provides temporary relief from default provisions to facilitate debt restructuring- -Company to host conference call to prov |
|
| May 29, 2012 |
CUSIP No. 904753100 13D/A Page 1 of 11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934 Unigene Laboratories, Inc. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 904753100 (CUSIP Number) Wynnefield Partners Small Cap Value, L.P. 450 Seventh Avenue, Suite 509 Ne |
|
| May 22, 2012 |
Exhibit 99.1 Unigene’s Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies Company expects to commence Phase 1 clinical testing in humans in 1H 2013 May 22, 2012 –BOONTON, N.J. - (BUSINESS WIRE) - Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufa |
|
| May 22, 2012 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizatio |
|
| May 10, 2012 |
EXHIBIT 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”), dated as of March 15, 2012, is entered into by and between Unigene Laboratories, Inc., a Delaware corporation (the “Company”), and David Moskowitz (the “Executive”). WITNESSETH: WHEREAS, the Company desires to employ the Executive and to enter into this Agreement embodying the terms of such employment; and WHEREAS, the Exec |
|
| May 10, 2012 |
EX-10.2 3 ex10-2.htm EXHIBIT 10.2 EXHIBIT 10.2 March 26, 2012 Mr. Brian Zietsman 2 Hoyt Street Madison, NJ 07940 Re: Offer of At-Will Employment Dear Brian, On behalf of Unigene Laboratories, Inc. (“Unigene” or the “Company”), I am delighted to extend to you an offer of employment as Executive Director, Finance. This letter will serve to set forth the terms of our offer and your at-will employment |
|
| May 10, 2012 |
10-Q 1 unge10q-033112.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| May 7, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organization |
|
| May 7, 2012 |
Exhibit 99.1 Unigene Announces First Quarter 2012 Financial Results -Company’s highest priority challenge to address debt and restructure balance sheet- MAY 7, 2012 – BOONTON, N.J. - Unigene Laboratories, Inc. (OTCBB: UGNE), today announced financial results for the first quarter ended March 31, 2012. First Quarter 2012 Financial Summary Unigene announced that its net loss for the three months end |
|
| April 30, 2012 |
Annual Report - FORM 10-K/A (AMENDMENT NO. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 0-16005 UNIGEN |
|
| April 30, 2012 |
Exhibit 31.2(a) CERTIFICATION I, Brian Zietsman, certify that: 1. I have reviewed this Annual Report on Form 10-K/A Amendment No. 1 of Unigene Laboratories, Inc.; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were mad |
|
| April 30, 2012 |
Exhibit 31.1(a) CERTIFICATION I, Ashleigh Palmer, certify that: 1. I have reviewed this Annual Report on Form 10-K/A Amendment No. 1 of Unigene Laboratories, Inc.; and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were ma |
|
| April 9, 2012 |
ugne201204068k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorpor |
|
| April 3, 2012 |
Financial Statements and Exhibits, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation) (Commission File |
|
| April 3, 2012 |
EX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 Unigene’s Proprietary Oral Peptide Delivery Platform is Further Validated with Cara Therapeutics’ Successful Completion of its Phase 1 Study Using Unigene’s Oral Formulation of Novel Kappa Opioid Receptor Agonist, CR845 Robust 16% bioavailability and pharmacologic activity demonstrated with Unigene’s oral formulation APRIL 3, 2012 – BOONTON, N.J. - U |
|
| April 2, 2012 |
Exhibit 99.1 UNIGENE APPOINTS JACK WYSZOMIERSKI TO ITS BOARD OF DIRECTORS Board strengthened with extensive finance and biopharma/healthcare industry expertise APRIL 2, 2012 – BOONTON, N.J. - Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics today announced the appointment of Jack Wyszomierski to its Board of Direc |
|
| April 2, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizati |
|
| March 22, 2012 |
Exhibit 99.1 SUPREME COURT DENIES APOTEX’S PETITION FOR A WRIT OF CERTIORARI -Decision of the United States Court of Appeals Validating the Fortical® Patent in Favor of Unigene Stands as the Final Decision- MARCH 22, 2012 – BOONTON, N.J. - Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics today reported that the U. |
|
| March 22, 2012 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizat |
|
| March 16, 2012 |
Exhibit 99.1 UNIGENE APPOINTS DAVID MOSKOWITZ AS CHIEF FINANCIAL OFFICER Top-rated equity research veteran and distinguished pharmaceutical industry and Wall Street thought leader to drive Unigene’s strategic financial and capital markets efforts MARCH 15, 2012 – BOONTON, N.J. - Unigene Laboratories, Inc. (OTCBB: UGNE), today announced the appointment of David Moskowitz, RPh, MBA, to the position |
|
| March 16, 2012 |
ugne201203158k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorpo |
|
| March 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizat |
|
| March 15, 2012 |
10-K 1 unigene10k-123111.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file nu |
|
| March 15, 2012 |
Note: Certain portions of this document have been marked “[c.i.]” to indicate that confidential treatment has been requested for this confidential information. The confidential portions have been omitted and filed separately with the Securities and Exchange Commission. Exhibit 10.73 EXECUTION COPY MASTER AGREEMENT FOR JOINT DEVELOPMENT VEHICLE by and between Unigene Laboratories, Inc., a Delaware |
|
| March 15, 2012 |
Common Stock Purchase and Option Agreement EX-10.74 3 ex10-74.htm EXHIBIT 10.74 Exhibit 10.74 EXECUTION VERSION Common Stock Purchase and Option Agreement This Common Stock Purchase and Option Agreement (the “Agreement”) is made as of October 5, 2011, by and between Unigene Laboratories, Inc., a Delaware corporation (the “Company”) and Den Danske Forskningsfond, a Danish Foundation (“DDF”). Whereas, the Company desires to issue, and DDF de |
|
| March 8, 2012 |
EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 |
|
| March 8, 2012 |
Exhibit 99.1 Unigene Announces Fourth Quarter and Full-Year 2011 Results Proprietary, leading oral peptide drug delivery platform validated Company continuing successful execution of targeted growth strategy Priority challenge to address debt and restructure balance sheet Webcast and Conference Call scheduled for today at 11:00 a.m. ET MARCH 8, 2012 – BOONTON, N.J. - Unigene Laboratories, Inc. (OT |
|
| March 8, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizati |
|
| March 8, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organizati |
|
| March 5, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation) (Commission File |
|
| March 5, 2012 |
Exhibit 99.1 UNIGENE’S PROPRIETARY PEPTELLIGENCE™ PLATFORM SELECTED BY STEALTH PEPTIDES FOR AN ORAL PHASE 1 CLINICAL STUDY -Unigene signs Clinical Manufacturing Services Agreement with Stealth Peptides following successful outcome of feasibility studies- MARCH 5, 2012 – BOONTON, N.J. - Unigene Laboratories, Inc. (OTCBB: UGNE), today announced that the Company signed a Clinical Manufacturing Servic |
|
| January 23, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation) (Commissi |
|
| January 9, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organiza |
|
| January 9, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2012 Unigene Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 0-16005 22-2328609 (State or other jurisdiction of incorporation or organiza |
|
| January 9, 2012 |
Exhibit 99.1 |
|
| January 9, 2012 |
Exhibit 99.1 UNIGENE PROVIDES 2012 BUSINESS OUTLOOK -Company to continue successful execution of targeted growth strategy to monetize assets and unlock significant shareholder value- -Management and Board signal unified commitment and comprehensive vote of confidence and optimism with open market stock purchases- -Key elements in place to address debt and restructure balance sheet- January 9, 2012 |
